新型抗血小板药物普拉格雷、替格瑞洛与氯吡格雷的临床对比研究进展

[1] CYP2C19*2 and*17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (12) : 1280 - 1287

[2] Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention[J] . Dimitrios Alexopoulos,Anastasia Galati,Ioanna Xanthopoulou,Eleni Mavronasiou,George Kassimis,Konstantinos C. Theodoropoulos,George Makris,Anastasia Damelou,Grigorios Tsigkas,George Hahalis,Periklis Davlouros.Journal of the American College of Cardiology . 2012 (3)

[3] A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents[J] . Dietmar Trenk,Gregg W. Stone,Meinrad Gawaz,Adnan Kastrati,Dominick J. Angiolillo,Ulrike Müller,Gert Richardt,Joseph A. Jakubowski,Franz-Josef Neumann.Journal of the American College of Cardiology . 2012 (24)

[4] The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting [J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (03): : 169 - 175

[5] Antiplatelet therapy in acute coronary syndromes [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (01) : 27 - 42

[6] A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study[J] . Gilles Montalescot,Leonardo Bolognese,Dariusz Dudek,Patrick Goldstein,Christian Hamm,Jean-Francois Tanguay,Jur ten Berg,Petr Widimsky,Junxiang Luo,Debra L. Miller,Jochen Goedicke.American Heart Journal . 2011 (4)

[7] Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery[J] . Journal of the American College of Cardiology . 2011 (6)

[8] Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes （PLATO）: a randomised double-blind study[J] . The Lancet . 2010 (9711)

[9] New P2Y 12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention[J] . Anne Bellemain-Appaix,David Brieger,Farzin Beygui,Johanne Silvain,Ana Pena,Guillaume Cayla,Olivier Barthélémy,Jean-Philippe Collet,Gilles Montalescot.Journal of the American College of Cardiology . 2010 (19)

[10] Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes[J] . Giuseppe Biondi-Zoccai,Marzia Lotrionte,Pierfrancesco Agostoni,Antonio Abbate,Enrico Romagnoli,Giuseppe Sangiorgi,Dominick J. Angiolillo,Marco Valgimigli,Luca Testa,Fiorenzo Gaita,Imad Sheiban.International Journal of Cardiology . 2010 (3)

[1] CYP2C19*2 and*17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (12) : 1280 - 1287

[2] Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention[J] . Dimitrios Alexopoulos,Anastasia Galati,Ioanna Xanthopoulou,Eleni Mavronasiou,George Kassimis,Konstantinos C. Theodoropoulos,George Makris,Anastasia Damelou,Grigorios Tsigkas,George Hahalis,Periklis Davlouros.Journal of the American College of Cardiology . 2012 (3)

[3] A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents[J] . Dietmar Trenk,Gregg W. Stone,Meinrad Gawaz,Adnan Kastrati,Dominick J. Angiolillo,Ulrike Müller,Gert Richardt,Joseph A. Jakubowski,Franz-Josef Neumann.Journal of the American College of Cardiology . 2012 (24)

[4] The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting [J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (03): : 169 - 175

[5] Antiplatelet therapy in acute coronary syndromes [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (01) : 27 - 42

[6] A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study[J] . Gilles Montalescot,Leonardo Bolognese,Dariusz Dudek,Patrick Goldstein,Christian Hamm,Jean-Francois Tanguay,Jur ten Berg,Petr Widimsky,Junxiang Luo,Debra L. Miller,Jochen Goedicke.American Heart Journal . 2011 (4)

[7] Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery[J] . Journal of the American College of Cardiology . 2011 (6)

[8] Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes （PLATO）: a randomised double-blind study[J] . The Lancet . 2010 (9711)

[9] New P2Y 12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention[J] . Anne Bellemain-Appaix,David Brieger,Farzin Beygui,Johanne Silvain,Ana Pena,Guillaume Cayla,Olivier Barthélémy,Jean-Philippe Collet,Gilles Montalescot.Journal of the American College of Cardiology . 2010 (19)

[10] Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes[J] . Giuseppe Biondi-Zoccai,Marzia Lotrionte,Pierfrancesco Agostoni,Antonio Abbate,Enrico Romagnoli,Giuseppe Sangiorgi,Dominick J. Angiolillo,Marco Valgimigli,Luca Testa,Fiorenzo Gaita,Imad Sheiban.International Journal of Cardiology . 2010 (3)